Kailera Therapeutics (NASDAQ:KLRA) Now Covered by JPMorgan Chase & Co.

Posted by Geri Gentry on May 12th, 2026

Analysts at JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) in a research note issued on Tuesday. The firm set an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 30.83% from the stock’s current price.

A number of other brokerages also recently weighed in on KLRA. TD Cowen initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday. They set a “buy” rating and a $57.00 target price for the company. Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. William Blair initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating for the company. Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday. They set a “buy” rating and a $48.00 target price for the company. Finally, Evercore initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kailera Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $42.75.

View Our Latest Report on KLRA

Kailera Therapeutics Stock Up 6.8%

Shares of NASDAQ KLRA opened at $22.93 on Tuesday. Kailera Therapeutics has a fifty-two week low of $20.86 and a fifty-two week high of $28.23.

Insider Activity at Kailera Therapeutics

In other news, Director Andrew T. Kaplan purchased 8,398,438 shares of Kailera Therapeutics stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the transaction, the director directly owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. The trade was a 47.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Adam Koppel purchased 1,562,500 shares of Kailera Therapeutics stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the transaction, the director directly owned 22,583,268 shares of the company’s stock, valued at $361,332,288. This represents a 7.43% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 10,460,938 shares of company stock valued at $167,375,008 over the last 90 days.

About Kailera Therapeutics

(Get Free Report)

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.